版本:
中国

BRIEF-Loxo Oncology announces FDA orphan drug designation granted to larotrectinib

May 12 Loxo Oncology Inc:

* Loxo Oncology announces FDA orphan drug designation granted to larotrectinib for the treatment of solid tumors with ntrk-fusion proteins Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐